Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2202)	12/1/2000 8:48:47 PM
From: Biomaven	Read Replies (3) \| Respond to of 52153

I only caught part of the Supreme Court audio today. What I did catch was way over my head - Tribe and Scalia duelling over some esoteric issue of whether the Florida court used the Florida constitution in reaching its decision, which apparently would have been a Bad Thing. So much for my hopes of a simple unanimous decision... This article on today's action is a nice one: slate.msn.com Peter

To: Biomaven who wrote (2202)	12/2/2000 1:05:12 AM
From: keokalani'nui	Respond to of 52153

>>GlaxoSmithKline will take the idea one stage further by designating each site, to be called centres for excellence in drug discovery, as competing profit centres. They will buy and sell services from the central organisation.<< I have some insight into this type of situation. If it were not a tired, discredited idea it would be funny. I give it 18 months. What an enormous incongruity in and of itself...R&D a profit center? How can and how likely are you to measure competition/success between scientific groups in shorter than a 10 year operating cycle? And, well, buying and selling from yourself is both prohibited by accounting principles and contrary to operating efficiency. Whoa, I really trashed that. Let me step back. I'm sure they know more than me. I'm sure they have consultants involved, good ones you know who have studied lots of manufacturing and marketing companies before advising pharmas. What is the definition of a consultant anyway? (Sorry if this is less than fresh.) A guy who takes your watch and tells you what time it is. >>But then again there's the data point I have from a friend at a fairly recent IPO that's been selling services to both pharmas and biotechs. His view: "Good luck trying to get a phone call returned from a pharma after lunch on a Friday..."<< Ahh, one simple observation illuminates so much. --Wilder

To: Biomaven who wrote (2202)	12/2/2000 7:56:36 PM
From: tommysdad	Read Replies (3) \| Respond to of 52153

<<But then again there's the data point I have from a friend at a fairly recent IPO that's been selling services to both pharmas and biotechs. His view: "Good luck trying to get a phone call returned from a pharma after lunch on a Friday...">> Well, sometimes breakthrough drugs do actually come from pharma: biz.yahoo.com STI-571 is truly remarkable. And unlikely to have come from a biotech, IMO. Novartis was in the kinase game big and early.